Back to Search
Start Over
Oruka Therapeutics initiated with bullish view at Stifel, here's why
- Source :
- The Fly. October 10, 2024
- Publication Year :
- 2024
-
Abstract
- Stifel initiated coverage of Oruka Therapeutics with a Buy rating and $49 price target. The firm views the rapid uptake of Bimzelx in psoriasis since U.S. approval in 2023 as [...]
- Subjects :
- Psoriasis
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.811829732